732
Participants
Start Date
September 24, 2013
Primary Completion Date
March 16, 2016
Study Completion Date
March 16, 2016
Bivalirudin
Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
Unfractionated Heparin
Unfractionated heparin is an anticoagulant.
Weill Cornell Medical College, New York
Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center, New York
Stony Brook Medicine, Stony Brook
INOVA Alexandria Hospital, Alexandria
University of Virginia Health System, Charlottesville
LeBauer Cardiovascular Research Foundation, Greensboro
Novant Health Heart and Vascular Institute, Charlotte
Medical University of South Carolina, Charleston
AnMed Health, Anderson
Florida Research Network, Gainesville
The Cardiac and Vascular Institute, Gainesville
Florida Hospital, Orlando
Baptist Cardiac & Vascular Institute, Miami
Clearwater Cardiovascular and Interventional Consultants, Clearwater
Kentucky Heart Foundation - King's Daughters Medical Center, Ashland
Jobst Vascular Institute, Toledo
Cleveland Clinic Foundation, Cleveland
University of Cincinnati, Cincinnati
Michigan Heart, Ypsilanti
Midwest Cardiovascular Research Foundation, Davenport
Medical College of Wisconsin, Milwaukee
Mayo Clinic, Rochester
Peoria Radiology Research & Education Foundation, Peoria
Tri-Lakes Research, Hot Springs
Integris - Baptist Medical Center, Oklahoma City
Scott and White Hospital, Temple
Texas Tech University Health Science Center, Lubbock
Alpine Research, Ogden
New Mexico Heart Institute, Albuquerque
Swedish Medical Center, Seattle
Stanford Hospital and Clinics, Stanford
Tufts Medical Center, Boston
VA Boston Healthcare System, Boston
Beth Israel Deaconess Medical Center, Boston
Cape Cod Research Institute, Hyannis
Deborah Heart and Lung Center, Browns Mills
Holy Name Medical Center, Teaneck
Rhode Island Hospital, Providence
Lead Sponsor
The Medicines Company
INDUSTRY